Organisation paid for research Program year 2025 Source: CMS Open Payments

Yuma Clinical Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$532,913

27 payments

Through program year 2025, Yuma Clinical Trials LLC is reported as receiving $532,913 in research payments, across 27 payments.

By program year

3 rows

Year	Kind	Amount	Payments
2025	Research	$149,766	15
2024	Research	$296,172	7
2023	Research	$86,975	5

Breakdown

Who paid Research payments · program years 2023–2025

Eli Lilly and Company $451,839 10 payments
Sanofi US Services Inc. $43,058 8 payments
Genentech, Inc. $38,016 9 payments

Studies the money was for Research payments · program years 2023–2025

A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight and Type 2 Diabetes (Attain-2) $352,391 4 payments
A Phase 3 Randomized Double Blind Study to Investigate the Efficacy and Safety of Once Daily Oral Ly3502970 Compared With Placebo in Adult Participants With Obesity Or Overweight and Type 2 Diabetes (Attain-2) $72,751 2 payments
CT-388-104 OW/OB with T2D $38,016 9 payments
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma $25,098 2 payments
A Phase 2B Double-Blind, Randomized, Placebo-Controlled Study of Bimagrumab and Tirzepatide, Alone Or in Combination, to Investigate the Efficacy and Safety in Adult Participants With Obesity Or Overweight With Type 2 Diabetes $23,331 2 payments
A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naive People With Type 2 Diabetes Mellitus and Renal Impairment: TRENT Trial $17,960 6 payments
Efficacy and Safety of Ixekizumab Or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-To-Severe Plaque Psoriasis and Obesity Or Overweight: A Phase 3B, Randomized, Multicenter, Open-Label Study (Together-Pso) $3,367 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.